Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases.

ABSTRACT:

Background

An advance in the treatment of schizophrenia is the development of long-acting intramuscular formulations of antipsychotics, such as olanzapine long-acting injection (LAI). During clinical trials, a post-injection syndrome characterized by signs of delirium and/or excessive sedation was identified in a small percentage of patients following injection with olanzapine LAI.

Methods

Safety data from all completed and ongoing trials of olanzapine LAI were reviewed for possible cases of this post-injection syndrome. Descriptive analyses were conducted to characterize incidence, clinical presentation, and outcome. Regression analyses were conducted to assess possible risk factors.

Results

Based on approximately 45,000 olanzapine LAI injections given to 2054 patien

SUBMITTER: Detke HC 

PROVIDER: S-EPMC2895589 | biostudies-literature | 2010 Jun

REPOSITORIES: biostudies-literature